Chimeric antigen receptor T cells

xlomafota13 shared this article with you from Inoreader Chimeric antigen receptor T cells Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S55-S64. doi: 10.1016/j.bulcan.2021.08.003. ABSTRACT Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T. In indolent B cell lymphomas, their efficacy has been established by recent clinical trials. Longer follow-up evaluation is needed to determine their added value in a field where approved strategies already provide high long-term survival rates. They will also be challenged by another immunotherapy with bispecific antibodies. In chronic lymphoid leukemia, early phase trials have identified several limitations related to the immune context of this disease, but associations with targeted therapy like ibrutinib are very promising. In this moving therapeutic landscape, molecular and cellular eng ineering progress will increase the capacities of these new cellular-based therapies. PMID:34920808 | DOI:10.1016/j.bulcan.2021.08.003 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.